KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer
Kinesin family member C1 (<i>KIFC1</i>), a minus end-directed motor protein, is reported to play an essential role in cancer. This study aimed to analyze <i>KIFC1</i> expression and examine <i>KIFC1</i> involvement in cisplatin resistance in bladder cancer (BC). I...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/73f7bc82541044febfe156f830d7a528 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Kinesin family member C1 (<i>KIFC1</i>), a minus end-directed motor protein, is reported to play an essential role in cancer. This study aimed to analyze <i>KIFC1</i> expression and examine <i>KIFC1</i> involvement in cisplatin resistance in bladder cancer (BC). Immunohistochemistry showed that 37 of 78 (47.4%) BC cases were positive for <i>KIFC1</i>. <i>KIFC1</i>-positive cases were associated with high T stage and lymph node metastasis. Kaplan-Meier analysis showed that <i>KIFC1</i>-positive cases were associated with poor prognosis, consistent with the results from public databases. Molecular classification in several public databases indicated that <i>KIFC1</i> expression was increased in basal type BC. Immunohistochemistry showed that <i>KIFC1</i>-positive cases were associated with basal markers 34βE12, CK5 and CD44. <i>KIFC1</i> expression was increased in altered <i>TP53</i> compared to that in wild-type <i>TP53</i>. Immunohistochemistry showed that <i>KIFC1</i>-positive cases were associated with p53-positive cases. P53 knockout by CRISPR-Cas9 induced <i>KIFC1</i> expression in BC cell lines. Knockdown of <i>KIFC1</i> by siRNA increased the sensitivity to cisplatin in BC cells. Kaplan-Meier analysis indicated that prognosis was poor among <i>KIFC1</i>-positive BC patients treated with cisplatin-based chemotherapy. Immunohistochemistry showed that <i>KIFC1</i>-positive cases were associated with PD-L1-positive cases. High <i>KIFC1</i> expression was associated with a favorable prognosis in patients treated with atezolizumab from the IMvigor 210 study. These results suggest that <i>KIFC1</i> might be a promising biomarker and therapeutic target in BC. |
|---|